Kinnate Biopharma (KNTE): Price and Financial Metrics
KNTE Price/Volume Stats
| Current price | $2.65 | 52-week high | $7.18 |
| Prev. close | $2.66 | 52-week low | $1.04 |
| Day low | $2.64 | Volume | 2,812,200 |
| Day high | $2.68 | Avg. volume | 418,678 |
| 50-day MA | $2.48 | Dividend yield | N/A |
| 200-day MA | $2.27 | Market Cap | 125.15M |
KNTE Stock Price Chart Interactive Chart >
Kinnate Biopharma (KNTE) Company Bio
Kinnate Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA.
Latest KNTE News From Around the Web
Below are the latest news stories about KINNATE BIOPHARMA INC that investors may wish to consider to help them evaluate KNTE as an investment opportunity.
13 Hot Penny Stocks To Buy According to Hedge FundsIn this article, we will take a look at the 13 Hot Penny Stocks To Buy According to Hedge Funds. To see more hot penny stocks, go directly to 5 Hot Penny Stocks To Buy According to Hedge Funds. The overall market optimism helped by expectations that the Fed might start cutting interest rates in […] |
Kinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist InvestorsOrbiMed Advisors is part of a partnership interested in acquiring all of Kinnate Biopharma. Baker Brothers increased an investment in Madrigal Pharmaceuticals. |
OrbiMed Advisors LLC Reduces Stake in Kinnate Biopharma IncOn November 13, 2023, OrbiMed Advisors LLC executed a significant stock transaction, reducing its holdings in Kinnate Biopharma Inc (NASDAQ:KNTE). The firm sold 450,000 shares at a trade price of $1.40, impacting its portfolio by a mere -0.01%. This move altered OrbiMed Advisors LLC's position in Kinnate Biopharma Inc to 7,559,729 shares, which now represents 0.19% of their investment portfolio and 16.00% of the company's outstanding shares. |
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesReported promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor Investigational New Drug application and nominate a drug candidate for brain-penetrant CDK4 selective program in the fourth quarter of 2023Previously announced strategic reprioritization with a focus on exarafenib combination in NRAS mutant melanoma, c-MET inhibitor KIN-8741 and brain penetrant CDK4 selectiv |
Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's WhyKinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization efforts and slash workforce by 70%. |
KNTE Price Returns
| 1-mo | 0.00% |
| 3-mo | 10.88% |
| 6-mo | 132.46% |
| 1-year | -10.17% |
| 3-year | -90.15% |
| 5-year | N/A |
| YTD | 11.81% |
| 2023 | -61.15% |
| 2022 | -65.58% |
| 2021 | -55.46% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...